Table 1.

Clinical characteristics of 10 patients with neuroblastoma

Case	Age group	Primary lesion and pathology	Metastatic site	NSE (ng/mL)	LDH (U/L)	VMA/Crn and HVA/Crn (μmol/mmol)	MYCN	1 p and 11q
1	Early childhood	R adrenal/poorly differentiated NB	Lung/bone marrow/bone	430	1271	/	Normal	Imbalance/normal
2	Early childhood	R adrenal/poorly differentiated NB	Lung/bone marrow/bone/distant lymph node/liver	1115	2812	/	Amplification	Imbalance/deletion
3*	Early adolescence	L adrenal/poorly differentiated NB	Lung/distant lymph node/liver	176	378	349.207/27.402	Normal	Imbalance/normal
4*	Early childhood	R adrenal/poorly differentiated NB	Lung	805	1381	/	Gain	Normal/normal
5	Early childhood	L adrenal/poorly differentiated NB	Lung/bone marrow/bone	750	2339	1.792/750.336	Amplification	Deletion/normal
6	Middle childhood	L adrenal/poorly differentiated NB	Lung/bone marrow/bone	694.5	1019	109.457/23.194	Gain	Deletion/normal
7	Early childhood	R adrenal/differentiated NB	Lung/bone marrow/bone/distant lymph node/liver	475.5	2059	27.617/3.980	Amplification	Deletion/gain
8	Early childhood	Posterior mediastinum/poorly differentiated NB	Lung/bone marrow/bone/distant lymph node/liver	685	1599	1386/98.276	Gain	Normal/deletion
9	Middle childhood	L Adrenal/poorly differentiated NB	Lung/liver	910	1123	/	Normal	Normal/normal
10	Early childhood	R adrenal/undifferentiated NB	Lung/distant lymph node	1030	4214	/	Amplification	Deletion/normal

Normal range: NSE (≤25 ng/mL); LDH (110–295 U/L); VMA/Crn (0.954–9.348 μmol/mmol); HVA/Crn (1.081–9.740 μmol/mmol).

*ALK status: Case 3: no ALK variation. Case 4: ALK mutation (Exon 23). The other 8 patients were not assessed for ALK status.

ALK, anaplastic lymphoma kinase; Crn, creatinine; HVA, homovanillic acid; L, left; LDH, lactate dehydrogenase; MYCN, N-myc proto-oncogene; NB, neuroblastoma; NSE, neuron-specific enolase; 1p/11q, chromosomal 1p and 11q alterations; R, right; VMA, vanillylmandelic acid.